ClinConnect ClinConnect Logo
Search / Trial NCT06327984

Barts Sex-CAD Database - Sex Hormones and Inflammatory Status in Coronary Artery Disease

Launched by QUEEN MARY UNIVERSITY OF LONDON · Mar 22, 2024

Trial Information

Current as of July 27, 2025

Recruiting

Keywords

Coronary Artery Disease Acute Coronary Syndrome Myocardial Infarction Sex Characteristics Hormones Inflammation

ClinConnect Summary

This clinical trial, called the Barts Sex-CAD Database, is investigating how sex hormones and inflammation might affect the development of coronary artery disease (CAD) in both men and women. CAD is a condition where the arteries that supply blood to the heart become blocked, which can lead to heart attacks. The researchers are particularly interested in understanding why women seem to be protected from CAD before menopause but have increased risks after, as well as why women who experience heart attacks face higher risks of having another one compared to men.

To participate in this study, you need to be at least 16 years old and present with chest pain at Barts Heart Centre. If you join, you will have your blood tested for inflammation markers and will answer questions about your hormone levels and medical history. This information will help the researchers learn more about how hormones and inflammation contribute to CAD, especially in women, with the hope of finding new treatments. If you have been treated at the center before, they may also reach out to you by phone for your input. Your participation could help improve heart care for everyone.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Any patient presenting with chest pain ≥16 years to Barts Heart Centre Will be included.
  • Exclusion Criteria:
  • Patients \<16 years will be excluded and adults lacking capacity will be excluded.

About Queen Mary University Of London

Queen Mary University of London is a prestigious research-intensive institution recognized for its commitment to advancing medical science and improving health outcomes. As a leading sponsor of clinical trials, the university harnesses its academic excellence and innovative research capabilities to explore groundbreaking treatments and therapies across various medical disciplines. With a focus on collaboration, the institution engages with a diverse network of clinicians, researchers, and industry partners to ensure rigorous study design, ethical conduct, and the translation of research findings into clinical practice. Queen Mary University of London is dedicated to contributing to the global body of knowledge in healthcare through high-quality clinical research that prioritizes patient safety and welfare.

Locations

London, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Krishnaraj Rathod, MBBS PhD

Principal Investigator

Queen Mary University of London

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported